Skip to main content
Top
Published in: BMC Health Services Research 1/2014

Open Access 01-12-2014 | Research article

Claims-based algorithms for identifying Medicare beneficiaries at high estimated risk for coronary heart disease events: a cross-sectional study

Authors: Evan L Thacker, Paul Muntner, Hong Zhao, Monika M Safford, Jeffrey R Curtis, Elizabeth Delzell, Vera Bittner, Todd M Brown, Emily B Levitan

Published in: BMC Health Services Research | Issue 1/2014

Login to get access

Abstract

Background

Databases of medical claims can be valuable resources for cardiovascular research, such as comparative effectiveness and pharmacovigilance studies of cardiovascular medications. However, claims data do not include all of the factors used for risk stratification in clinical care. We sought to develop claims-based algorithms to identify individuals at high estimated risk for coronary heart disease (CHD) events, and to identify uncontrolled low-density lipoprotein (LDL) cholesterol among statin users at high risk for CHD events.

Methods

We conducted a cross-sectional analysis of 6,615 participants ≥66 years old using data from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study baseline visit in 2003–2007 linked to Medicare claims data. Using REGARDS data we defined high risk for CHD events as having a history of CHD, at least 1 risk equivalent, or Framingham CHD risk score >20%. Among statin users at high risk for CHD events we defined uncontrolled LDL cholesterol as LDL cholesterol ≥100 mg/dL. Using Medicare claims-based variables for diagnoses, procedures, and healthcare utilization, we developed algorithms for high CHD event risk and uncontrolled LDL cholesterol.

Results

REGARDS data indicated that 49% of participants were at high risk for CHD events. A claims-based algorithm identified high risk for CHD events with a positive predictive value of 87% (95% CI: 85%, 88%), sensitivity of 69% (95% CI: 67%, 70%), and specificity of 90% (95% CI: 89%, 91%). Among statin users at high risk for CHD events, 30% had LDL cholesterol ≥100 mg/dL. A claims-based algorithm identified LDL cholesterol ≥100 mg/dL with a positive predictive value of 43% (95% CI: 38%, 49%), sensitivity of 19% (95% CI: 15%, 22%), and specificity of 89% (95% CI: 86%, 90%).

Conclusions

Although the sensitivity was low, the high positive predictive value of our algorithm for high risk for CHD events supports the use of claims to identify Medicare beneficiaries at high risk for CHD events.
Appendix
Available only for authorised users
Literature
2.
go back to reference Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Coordinating Committee of the National Cholesterol Education Program: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004, 110: 227-239. 10.1161/01.CIR.0000133317.49796.0E.CrossRefPubMed Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Coordinating Committee of the National Cholesterol Education Program: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004, 110: 227-239. 10.1161/01.CIR.0000133317.49796.0E.CrossRefPubMed
3.
go back to reference Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PWF: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. in press Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PWF: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. in press
4.
go back to reference Mann DM, Woodward M, Muntner P, Falzon L, Kronish I: Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010, 44: 1410-1421. 10.1345/aph.1P150.CrossRefPubMedPubMedCentral Mann DM, Woodward M, Muntner P, Falzon L, Kronish I: Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010, 44: 1410-1421. 10.1345/aph.1P150.CrossRefPubMedPubMedCentral
5.
go back to reference Lemstra M, Blackburn D, Crawley A, Fung R: Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012, 28: 574-580. 10.1016/j.cjca.2012.05.007.CrossRefPubMed Lemstra M, Blackburn D, Crawley A, Fung R: Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012, 28: 574-580. 10.1016/j.cjca.2012.05.007.CrossRefPubMed
6.
go back to reference Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS, LAPLACE-TIMI 57 Investigators: Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled dose-ranging, phase 2 study. Lancet. 2013, 380: 2007-2017.CrossRef Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS, LAPLACE-TIMI 57 Investigators: Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled dose-ranging, phase 2 study. Lancet. 2013, 380: 2007-2017.CrossRef
7.
go back to reference McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA: Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012, 59: 2344-2353. 10.1016/j.jacc.2012.03.007.CrossRefPubMed McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA: Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012, 59: 2344-2353. 10.1016/j.jacc.2012.03.007.CrossRefPubMed
8.
go back to reference Platt R, Ommaya A: A beneficial side effect of the Medicare drug benefit. N Engl J Med. 2005, 353: 2742-3743. 10.1056/NEJMp058297.CrossRefPubMed Platt R, Ommaya A: A beneficial side effect of the Medicare drug benefit. N Engl J Med. 2005, 353: 2742-3743. 10.1056/NEJMp058297.CrossRefPubMed
9.
go back to reference Yun H, Delzell E, Ensrud KE, Kilgore ML, Becker D, Morrisey MA, Curtis JA: Predicting hip and major osteoporotic fractures using administrative data. Arch Intern Med. 2010, 170: 1940-1941.CrossRefPubMedPubMedCentral Yun H, Delzell E, Ensrud KE, Kilgore ML, Becker D, Morrisey MA, Curtis JA: Predicting hip and major osteoporotic fractures using administrative data. Arch Intern Med. 2010, 170: 1940-1941.CrossRefPubMedPubMedCentral
10.
go back to reference Schneeweiss S, Rassen JA, Glynn RJ, Myers J, Daniel GW, Singer J, Solomon DH, Kim S, Rothman KJ, Liu J, Avorn J: Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012, 12: 180-10.1186/1471-2288-12-180.CrossRefPubMedPubMedCentral Schneeweiss S, Rassen JA, Glynn RJ, Myers J, Daniel GW, Singer J, Solomon DH, Kim S, Rothman KJ, Liu J, Avorn J: Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012, 12: 180-10.1186/1471-2288-12-180.CrossRefPubMedPubMedCentral
11.
go back to reference Cutrona SL, Toh S, Iyer A, Foy S, Cavagnaro E, Forrow S, Racoosin JA, Goldberg R, Gurwitz JH: Design for validation of acute myocardial infarction cases in Mini-Sentinel. Pharmacoepidemiol Drug Saf. 2012, 21: 274-281.CrossRefPubMedPubMedCentral Cutrona SL, Toh S, Iyer A, Foy S, Cavagnaro E, Forrow S, Racoosin JA, Goldberg R, Gurwitz JH: Design for validation of acute myocardial infarction cases in Mini-Sentinel. Pharmacoepidemiol Drug Saf. 2012, 21: 274-281.CrossRefPubMedPubMedCentral
13.
go back to reference Harris TJ, Zafar AM, Murphy TP: Utilization of lower extremity arterial disease diagnostic and revascularization procedures in Medicare beneficiaries 2000–2007. AJR Am J Roentgenol. 2011, 197: W314-W317. 10.2214/AJR.10.6132.CrossRefPubMed Harris TJ, Zafar AM, Murphy TP: Utilization of lower extremity arterial disease diagnostic and revascularization procedures in Medicare beneficiaries 2000–2007. AJR Am J Roentgenol. 2011, 197: W314-W317. 10.2214/AJR.10.6132.CrossRefPubMed
14.
go back to reference Hirsch AT, Hartman L, Town RJ, Virnig BA: National healthcare costs of peripheral arterial disease in the Medicare population. Vasc Med. 2008, 13: 209-215. 10.1177/1358863X08089277.CrossRefPubMed Hirsch AT, Hartman L, Town RJ, Virnig BA: National healthcare costs of peripheral arterial disease in the Medicare population. Vasc Med. 2008, 13: 209-215. 10.1177/1358863X08089277.CrossRefPubMed
20.
go back to reference Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, Graham A, Moy CS, Howard G: The Reasons for Geographic and Racial Differences in Stroke study: objectives and design. Neuroepidemiology. 2005, 25: 135-143. 10.1159/000086678.CrossRefPubMed Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, Graham A, Moy CS, Howard G: The Reasons for Geographic and Racial Differences in Stroke study: objectives and design. Neuroepidemiology. 2005, 25: 135-143. 10.1159/000086678.CrossRefPubMed
21.
go back to reference Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA: High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009, 20: 512-522. 10.1097/EDE.0b013e3181a663cc.CrossRefPubMedPubMedCentral Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA: High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009, 20: 512-522. 10.1097/EDE.0b013e3181a663cc.CrossRefPubMedPubMedCentral
22.
go back to reference Steyerberg EW, Harrell FE, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD: Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001, 54: 774-781. 10.1016/S0895-4356(01)00341-9.CrossRefPubMed Steyerberg EW, Harrell FE, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD: Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001, 54: 774-781. 10.1016/S0895-4356(01)00341-9.CrossRefPubMed
Metadata
Title
Claims-based algorithms for identifying Medicare beneficiaries at high estimated risk for coronary heart disease events: a cross-sectional study
Authors
Evan L Thacker
Paul Muntner
Hong Zhao
Monika M Safford
Jeffrey R Curtis
Elizabeth Delzell
Vera Bittner
Todd M Brown
Emily B Levitan
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2014
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/1472-6963-14-195

Other articles of this Issue 1/2014

BMC Health Services Research 1/2014 Go to the issue